The results, based on serum samples prospectively collected in a cohort study, provide some support for the hypothesis that individuals with allergic sensitization are at reduced risk of glioma and confirm results from previous case-control studies. DOI: https://doi.org/10.1111/j. 1398-9995.2011.02670.x Posted at the Zurich Open Repository and Archive, University of Zurich ZORA URL: https://doi.org/10.5167/uzh-54311 Originally published at: Schlehofer, B; Siegmund, B; Linseisen, J; Schüz, J; Rohrmann, S; Becker, S; Michaud, D; Melin, B; Bas Bueno-de-Mesquita, H; Peeters, P H M; Vineis, P; Tjonneland, A; Olsen, A; Overvad, K; Romieu, I; Boeing, H; Aleksandrova, K; Trichopoulou, A; Bamia, C; Lagiou, P; Sacerdote, C; Palli, D; Panico, S; Sieri, S; Tumino, R; Sanchez, M-J; Rodriguez, L; Dorronsoro, M; Duell, E J; Chirlaque, M-D; Barricarte, A; Borgquist, S; Manjer, J; Gallo, V; Allen, N E; Key, T J; Riboli, E; Kaaks, R; Wahrendorf, J (2011). Primary brain tumours and specific serum immunoglobulin E: a case-control study nested in the European Prospective Investigation into Cancer and Nutrition cohort. Allergy, 66(11):1434-1441. DOI: https://doi.org/10.1111/j. 1398-9995.2011.02670 Abstract Background: Case-control studies suggest that patients with allergic diseases have a lower risk of developing glioma but not meningioma or schwannoma. However, those data can be differentially biased. Prospective studies with objective measurements of immunologic biomarkers, like immunoglobulin E (IgE), in blood obtained before cancer diagnosis could help to clarify whether an aetiological association exists.Methods: The present case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) measured specific serum IgE as a biomarker for the most common inhalant allergens in 275 glioma, 175 meningioma and 49 schwannoma cases and 963 matched controls using the ImmunoCAP specific